CLINICAL TRIALS PROFILE FOR PREVACID 24 HR

All Clinical Trials for PREVACID 24 HR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00204373 ↗	Treatment of Zollinger-Ellison Syndrome With Prevacid	Completed	Takeda Pharmaceuticals North America, Inc.	Phase 4	2003-03-01	The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
NCT00204373 ↗	Treatment of Zollinger-Ellison Syndrome With Prevacid	Completed	Charles Mel Wilcox, MD	Phase 4	2003-03-01	The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.
NCT00211614 ↗	Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea	Withdrawn	MetroHealth Medical Center	N/A	2006-07-01	Obstructive Sleep Apnea (OSA) is common in modern society, affecting up to 5% of working middle-aged adults in the United States. Obesity is the number one risk factor for the development of OSA. Consequences of untreated OSA are varied and significant and included numerous neuropsychiatric parameters such as mood alterations, depression, anxiety, diminished social interactions, and decreased quality of life. Mounting evidence suggests that treatment of OSA can improve many of these outcomes. The primary treatment modality for this condition is continuous positive airway pressure (CPAP). This device delivers positive pressure to the upper airway in order to prevent its collapse during sleep. Unfortunately, many patients do not choose to use CPAP or have difficulty with these devices. This results in many individuals with OSA either going without therapy or unable to reap the full benefits of treatment. Gastroesophageal reflux (GERD) is also common in the United States and may, in some instances, be directly related to weight gain. Survey studies have suggested that symptomatic GERD is more common in patients with OSA. Whether there exists a cause and effect relationship between these two conditions is not known at present. It has been suggested that GERD may contribute to OSA by narrowing the upper airway. This study will examine the effect of treatment of GERD on mild to moderate OSA. Fifty individuals identified as having mild to moderate OSA (diagnosed by overnight sleep study or PSG) and GERD (confirmed by an esophageal probe) will be enrolled. Both men and women will be included in this study and no "special populations" will be utilized. Subjects will fill out questionnaires to subjectively measure sleepiness, OSA-related symptoms, GERD-related symptoms, and sleep apnea-related quality of life. They will then be randomized to receive either 12 weeks of the proton pump inhibitor lansoprazole (Prevacid) or placebo (twenty five subjects per group). Upon completion of the 12 week trial, subjects will return and the following data will be collected; repeat all of the baseline questionnaires, repeat PSG and repeat pH probe. Results from this study will help to establish the relative effectiveness of a novel form of therapy for a common yet difficult to manage medical condition. . The risks to subjects enrolled in the study are minimal and therefore the benefit to risk ratio is heavily in favor of performing the study.
NCT00215787 ↗	Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease	Completed	Head and Neck Surgery Associates	N/A	2005-09-01	Although nasal polyposis has been recognized as an inflammatory process for many years, the true etiology of nasal polyposis mainly unknown. Despite surgical removal, the recurrence rate after surgery has been reported as high as 87% within the first year after surgery. Anecdotally the Principal Investigator found an incidence of pH probe-proven laryngopharyngeal reflux approaching 80% in his patients with nasal polyposis. Although his number of cases was small, the incidence of recurrence of polyps in these patients was 17%. The PI believes that such an association is too great to be explained by chance alone, and deserves further study. He anticipates two contributions to the literature from this study, the first documenting the incidence of extraesophageal (laryngopharyngeal) reflux in patients with polyposis, and the second showing the impact of reflux treatment on the recurrence rate of the polyps, initially after one year of therapy.
NCT00230516 ↗	Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects	Completed	AstraZeneca	Phase 4	2005-09-01	This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®

Clinical Trial Conditions for PREVACID 24 HR

Condition Name

Condition Name for PREVACID 24 HR
Intervention	Trials
Healthy	9
Gastroesophageal Reflux	6
Erosive Esophagitis	4
Asthma	3

Condition MeSH

Condition MeSH for PREVACID 24 HR
Intervention	Trials
Gastroesophageal Reflux	14
Esophagitis	6
Laryngopharyngeal Reflux	3
Ulcer	3

Clinical Trial Locations for PREVACID 24 HR

Trials by Country

Trials by Country for PREVACID 24 HR
Location	Trials
United States	123
China	68
Korea, Republic of	16
Malaysia	12
India	10

Trials by US State

Trials by US State for PREVACID 24 HR
Location	Trials
Missouri	7
California	7
Florida	6
Georgia	5
Ohio	5

Clinical Trial Progress for PREVACID 24 HR

Clinical Trial Phase

Clinical Trial Phase for PREVACID 24 HR
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for PREVACID 24 HR
Clinical Trial Phase	Trials
Completed	33
Terminated	5
Unknown status	2

Clinical Trial Sponsors for PREVACID 24 HR

Sponsor Name

Sponsor Name for PREVACID 24 HR
Sponsor	Trials
Takeda	8
AstraZeneca	6
TAP Pharmaceutical Products Inc.	6

Sponsor Type

Sponsor Type for PREVACID 24 HR
Sponsor	Trials
Other	42
Industry	31
NIH	2

PREVACID 24HR: Clinical Trial Update, Market Analysis, and Projections

Last updated: February 19, 2026

PREVACID 24HR (lansoprazole) is a proton pump inhibitor (PPI) used to treat frequent heartburn. This report details its current clinical trial landscape, market positioning, and future commercial trajectory.

What are the latest clinical trial developments for PREVACID 24HR?

The primary indication for PREVACID 24HR is the management of frequent heartburn, defined as occurring two or more days per week. The drug is approved for over-the-counter (OTC) use in this capacity in the United States. Clinical trials informing its current use focus on efficacy, safety, and patient-reported outcomes for this specific indication.

Key Clinical Trial Data and Status

• Indication: Treatment of frequent heartburn (occurring 2 or more days per week).
• Active Ingredient: Lansoprazole.
• Dosage Form: Delayed-release capsules for oral administration.
• Dosage Strength: 15 mg.
• Administration: Typically taken once daily for a 14-day course of treatment.
• Regulatory Status (US): Over-the-Counter (OTC) drug, approved by the Food and Drug Administration (FDA).
• Primary Efficacy Endpoints: Studies generally assess the percentage of heartburn-free days and nights during the 14-day treatment period and for a subsequent observation period. For example, trials have demonstrated that PREVACID 24HR can provide 24-hour heartburn relief with just one 15 mg delayed-release capsule taken once daily for 14 days. Specific trial data often report that a significant percentage of patients (e.g., over 50%) achieve complete relief from heartburn over the 14-day course.
• Safety Profile: Clinical trials establish a well-defined safety profile for lansoprazole at the 15 mg OTC dose. Common adverse events are generally mild and transient, including diarrhea, headache, constipation, and nausea. Long-term PPI use has been associated with potential risks, which are communicated via product labeling and physician guidance, though these are less directly applicable to the 14-day OTC treatment course for heartburn.
• Ongoing Research: While PREVACID 24HR is an established OTC product, ongoing pharmacovigilance and post-marketing surveillance are standard for all approved drugs. This includes monitoring for any new or emerging safety signals. Dedicated clinical trials for new indications or significant dosage modifications for PREVACID 24HR are not currently a primary focus, given its established OTC market position. Research in the broader PPI class continues, but this primarily relates to novel delivery systems, combination therapies, or exploration of mechanisms of action for other gastrointestinal disorders.

What is the market landscape for PREVACID 24HR?

PREVACID 24HR operates within the highly competitive OTC heartburn and acid indigestion market. Its market position is defined by its established brand recognition, efficacy for its intended use, and competition from both other PPIs and different classes of acid-reducing medications.

Market Segmentation and Competition

• Market Category: OTC gastrointestinal medications, specifically heartburn and acid reflux relief.
• Direct Competitors (Other PPIs - OTC):
  • Nexium 24HR (esomeprazole magnesium)
  • Prilosec OTC (omeprazole)
  • Zegerid OTC (omeprazole/sodium bicarbonate)
• Indirect Competitors (Other Acid Reducers - OTC):
  • H2 Receptor Blockers (H2RAs): Famotidine (e.g., Pepcid AC), Ranitidine (largely withdrawn from US market due to NDMA concerns), Cimetidine (Tagamet HB).
  • Antacids: Calcium carbonate (e.g., Tums), Aluminum hydroxide/Magnesium hydroxide (e.g., Maalox), Sodium bicarbonate.
• Key Market Drivers:
  • Prevalence of Heartburn: High incidence of occasional and frequent heartburn in the general population.
  • Consumer Awareness: Growing understanding of different medication classes for heartburn relief.
  • Direct-to-Consumer (DTC) Advertising: Significant marketing spend by major pharmaceutical companies to drive brand awareness and preference.
  • Accessibility: Widespread availability in pharmacies, supermarkets, and mass merchandisers.
  • Perceived Efficacy: Consumer perception of the effectiveness of PPIs for a 14-day course of treatment.

PREVACID 24HR's Competitive Advantages and Challenges

• Advantages:
  • Brand Recognition: PREVACID is a well-established brand name, inherited from its prescription counterpart.
  • Efficacy for 14-Day Treatment: Proven ability to provide relief from frequent heartburn over a defined course.
  • Established Safety Profile: Decades of clinical use and post-marketing data for lansoprazole.
• Challenges:
  • Intense Competition: The OTC market is saturated with similar products, including other PPIs with comparable efficacy for a 14-day course.
  • Price Sensitivity: Consumers may opt for lower-priced generic alternatives or competing brands based on promotions.
  • H2RA/Antacid Alternatives: Some consumers may prefer the rapid but short-lived relief of antacids or the faster onset of action of H2RAs for less frequent or less severe symptoms.
  • Long-Term Use Concerns: While PREVACID 24HR is for a 14-day course, general awareness of potential long-term risks associated with PPIs can influence consumer perception.

Market Share and Sales Data (Estimated)

Precise, publicly disclosed market share data for individual OTC drugs is not readily available. However, the OTC PPI market segment, which includes PREVACID 24HR, Nexium 24HR, and Prilosec OTC, is a significant portion of the overall heartburn relief market. Industry reports suggest that the global heartburn and acid reflux market is valued in the billions of dollars and is projected to grow. Within the PPI sub-segment, brands like Nexium 24HR and Prilosec OTC often lead in reported sales figures in major markets like the US, driven by extensive marketing and established consumer trust. PREVACID 24HR maintains a competitive position due to its brand equity.

What are the market projections for PREVACID 24HR?

The market projections for PREVACID 24HR are largely tied to the overall growth trends of the OTC heartburn and acid reflux market, with specific considerations for competitive pressures and evolving consumer preferences.

Growth Drivers and Restraints

• Growth Drivers:
  • Aging Population: Increased prevalence of GERD and related symptoms in older demographics.
  • Lifestyle Factors: High-stress levels, poor dietary habits (e.g., consumption of processed foods, fatty foods, spicy foods), and obesity contribute to increased heartburn incidence.
  • Consumer Education: Continued efforts to educate consumers about symptom management and the availability of OTC treatments.
  • Geographic Expansion (potential): If applicable, expansion into new or underdeveloped OTC markets.
• Restraints:
  • Genericization: While PREVACID 24HR is an OTC brand, generic availability of lansoprazole or competing PPIs could exert price pressure.
  • Shift to Prescription/Professional Guidance: For persistent or severe symptoms, consumers may be advised by healthcare professionals to seek prescription-strength medications or diagnostic evaluation, bypassing the OTC market.
  • Regulatory Scrutiny: Potential for increased regulatory oversight or warnings regarding long-term PPI use, even if PREVACID 24HR is intended for short-term use.
  • Development of Alternative Therapies: Emergence of new drug classes or non-pharmacological approaches for heartburn management.

Projected Market Performance

The OTC heartburn market is generally expected to experience stable to moderate growth. For PREVACID 24HR, its performance will likely mirror this trend, influenced by:

• Brand Loyalty and Awareness: Continued strong marketing campaigns can help sustain consumer engagement.
• Competitive Pricing: The ability to maintain competitive pricing against other OTC PPIs and H2RAs will be critical.
• Retailer Shelf Space and Promotions: Strategic partnerships with retailers are essential for visibility and sales volume.

Estimated Market Growth Rate (OTC Heartburn Segment): Industry analysts project the global heartburn and acid reflux market to grow at a compound annual growth rate (CAGR) of 3% to 5% over the next five to seven years. PREVACID 24HR's specific growth rate will depend on its ability to capture market share within this expanding but competitive landscape. It is projected to maintain its position as a significant player, but substantial market share gains against dominant brands like Nexium 24HR or Prilosec OTC will be challenging without significant differentiation or aggressive marketing.

Future Opportunities

• Targeted Marketing Campaigns: Focusing on specific demographics or lifestyle triggers for heartburn.
• Bundling or Combination Packs: While not currently prevalent for PREVACID 24HR, exploring combinations with other digestive aids could be a future avenue.
• Digital Health Integration: Leveraging digital platforms for consumer education and adherence reminders for the 14-day regimen.

Key Takeaways

PREVACID 24HR is an established OTC PPI for frequent heartburn, supported by a well-defined clinical profile for its 14-day treatment indication. The drug operates in a highly competitive OTC market, facing direct competition from other PPIs and indirect competition from H2RAs and antacids. Market growth is driven by lifestyle factors and an aging population, but intense competition and potential consumer shifts to other treatments pose challenges. Projections indicate stable to moderate growth for the OTC heartburn segment, with PREVACID 24HR expected to maintain its competitive presence through brand recognition and strategic marketing.

Frequently Asked Questions

1. What is the primary difference between PREVACID 24HR and prescription-strength lansoprazole? Prescription-strength lansoprazole is available in higher dosages (e.g., 30 mg) and is indicated for a broader range of gastrointestinal conditions, including erosive esophagitis, symptomatic gastroesophageal reflux disease (GERD), and duodenal ulcers. PREVACID 24HR is specifically formulated at a 15 mg dose for over-the-counter use to treat frequent heartburn.
2. How long should PREVACID 24HR be used? PREVACID 24HR is intended for a 14-day course of treatment to relieve frequent heartburn. It should not be used for more than 14 days or for more than two courses of treatment in a year, unless directed by a doctor.
3. Are there any long-term risks associated with taking PREVACID 24HR? While PREVACID 24HR is designed for short-term use (14 days), general warnings about long-term PPI use, which may include increased risk of bone fractures, certain nutrient deficiencies (e.g., magnesium, vitamin B12), and increased risk of C. difficile infection, are relevant to the class. However, these risks are primarily associated with prolonged, continuous daily use over months or years, not the 14-day regimen for PREVACID 24HR.
4. Can PREVACID 24HR be taken daily for ongoing heartburn management? No, PREVACID 24HR is not indicated for daily, continuous use for ongoing heartburn management. If heartburn persists or worsens, consumers are advised to consult a healthcare professional for a more comprehensive evaluation and treatment plan.
5. What is the typical onset of action for PREVACID 24HR? While PREVACID 24HR provides 24-hour acid control with a single daily dose, its onset of action for symptom relief may not be immediate. Unlike antacids which provide rapid but temporary relief, PPIs work by reducing acid production over time. Full symptom relief may take a few days of consistent daily dosing.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [2] Takeda Pharmaceuticals U.S.A., Inc. (2021). PREVACID 24HR (lansoprazole) Delayed-Release Capsules Full Prescribing Information. [3] Global Market Insights, Inc. (2023). Heartburn Treatment Market Size, Share & Trends Analysis Report. [4] Grand View Research. (2023). Heartburn and Acid Reflux Treatment Market Size, Share & Trends Analysis Report.